Narval logo

Narval

A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal and skin tissues

8 employees · est. 2023 · Knoxville, United States

VS
SAB BIO logo

SAB BIO

Working to transform treatment for people living with type 1 diabetes through a unique disease-modifying therapy

88 employees · est. 2014 · Miami, United States

SAB BIO is the older company (2023 vs 2014); SAB BIO is the larger of the two.

Side-by-Side Comparison

Narval SAB BIO
Founded
2023 2014 older
Headquarters
Knoxville, United States Miami, United States
Employees
8 88 larger
Industry
Biotechnology, Health and Wellness, Life Sciences Biotechnology, Health and Wellness
Funding Stage
Non Equity Assistance Post Ipo Equity
Total Funding
Not tracked yet $186.32M
Funding Rounds
1 7
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceuticals, Immunotherapeutics, Antibody Engineering, Antibody Drugs, Disease Treatment, Respiratory Diseases, Eye Diseases, Autoimmune Diseases, Skin Diseases, Mucosal Delivery, Skin Delivery, Antibody Mimetic Proteins, Immunotherapy, Life Sciences Biopharmaceuticals, Immunotherapy, Type 1 Diabetes, Clinical-stage, Disease-modifying, Antibody Therapeutics, Immunoglobulins, Antibody Science, Immunology, Autoimmune Diseases, Public Health, Rare Conditions, Long-term Diseases, Pandemic Threats
Website
narvalbio.com sab.bio
Narval logo

About Narval

Narval is a biotechnology startup founded in 2023, focusing on pioneering a new generation of antibody drugs using synthetic proteins that mimic the activity of antibodies. The company's slogan is "A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal...

SAB BIO logo

About SAB BIO

SAb Biotherapeutics is a biotechnology startup founded in 2014 and headquartered in the United States. The company is dedicated to developing a disease-modifying immunotherapy aimed at delaying the onset and progression of type 1 diabetes. They have a novel immunotherapy platform focused on developi...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Narval and SAB BIO — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Narval and SAB BIO — by email.

Frequently Asked Questions

Narval — A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal and skin tissues. SAB BIO — Working to transform treatment for people living with type 1 diabetes through a unique disease-modifying therapy. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Narval has raised undisclosed funding while SAB BIO has raised $186.32M.
Narval and SAB BIO operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Narval with someone else

Start typing a company name or domain.

Related Comparisons

One analytics cookie (Google Analytics). Cookie Policy